Page 4 - Biocon

R&D expenditure will rise in the coming quarters: Biocon Biologics MD

In a Q&A, Dr Arun Chandavarkar spoke on how its interchangeable insulin biosimilar has driven the business

Biocon rises over 3% as biotech major sees strong Dec qtr numbers

Notwithstanding the muted broader market trend, shares of Biocon Ltd surged over 3 per cent on Friday after the biotechnology major reported strong December quarter earnings. On BSE, the stock opened at Rs 363, then touched a high of Rs 382.45, registering a gain of 5.09 per cent over its last close. The stock finally ended at Rs 376.60, up 3.49 per cent. In a similar trend on NSE, the stock opened at Rs 364.00, then jumped 5.02 per cent and touched an early high of Rs 382.50 in initial deals. It finally settled at Rs 376.45, up 3.36 per cent. On Thursday, biotechnology major Biocon Ltd reported a 17.68 per cent rise in consolidated net profit at Rs 219.6 crore for the third quarter ended December 31, 2021. The company had posted a consolidated net profit of Rs 186.6 crore in the same quarter of the previous fiscal. Consolidated total income in the third quarter this fiscal stood at Rs 2,222.5 crore, compared to Rs 1,885.3 crore a year ago. The biosimilars vertical clocked revenue

Stocks to Watch: RIL, Asian Paints, HUL, BoM, PNB Housing, VodaIdea, Biocon

Bandhan Bank, HDFC Life, Hindustan Zinc, Voda Idea, Inox Leisure, JSW Steel, Kajaria Ceramics, L&T Fin Holdings, PVR, Reliance Industries, SBI Life and Supriya Lifescience to announce results today

Biocon consolidated net profit rises 18% to Rs 220 crore in Q3

Biosimilars vertical clocked revenue of Rs 981.4 crore as compared to Rs 768.9 crore in the same quarter last fiscal

Sensex falls for 3rd straight day, sheds 634 pts; Nifty holds 17,750

Analysts, however, expect markets to recover from here on as they have reached their key support zones.

USFDA rejects Biocon, Viatris application for Insulin Aspart

The company will respond to the CRL to satisfy the FDA's requests

Biocon Biologics partner Viatris wins favourable order from US court

Biocon Biologics Ltd, said its partner Viatris has won favourable decisions from a US federal court in Sanofi's challenge over unpatentability of device patents for disposable insulin injection pen

Trials start for Equillium drug for autoimmune disease after India approval

Equillium secured exclusive rights to develop and commercialise itolizumab for the US and Canada markets, in May 2017.

Trading strategies for Bandhan Bank & Ambuja Cement by Ajit Mishra

The stock of Bandhan Bank has been underperforming the banking index and is still struggling below the resistance zone of moving averages

Biocon in talks with Mylan to merge biosimilar businesses: Report

Indian drugmaker Biocon Ltd is in talks with generic drugmaker Mylan for a merger of their biosimilar businesses, a report said

Biocon ties up with Tabuk Pharmaceuticals to sell medicines in Middle East

Biocon said it has inked a pact with Saudi Arabia-based drug firm Tabuk Pharmaceutical Manufacturing Company to commercialise select speciality products in Middle East region

Biotechnology major Biocon gets USFDA approval for generic product

The product is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant

Biocon enters Dow Jones Sustainability Index in Emerging Markets category

Pharma major makes it to the DJSI EM Index with a total sustainability score of 45 as against an industry average of 18

Stocks to Watch: IndiGo, Biocon, Pfizer, IEX, TFCI, SAIL, BHEL, Nalco

Indian Energy Exchange and Apollo Pipes have announced their respective record dates for the issuance of bonus shares for eligible shareholders

Biocon Biologics, Viatris launch interchangeable insulin biosimilar for US

These injections will help control high blood sugar in adult and pediatric patients with type-1 diabetes and adults with type-2

Biocon starts campaign to treat diabetic children, train healthcare workers

India has one of the largest populations of children and adolescents living with Type 1 diabetes in the world with an estimated 1 million patients in this age group

Serum Alliance will give revenue stream from H2FY23: Biocon Biologics exec

In a Q&A, Shreehas Tambe talks about the road ahead for the firm's biosimilars business and how its alliance with Serum is projected to pan out

Ashok Leyland, Biocon look good on charts for a rebound: Ajit Mishra

The technical analyst from Religare Broking also recommends to accumulate United Spirits. Check out the range below

Biocon net rises 11% in Q2 to Rs 188 cr, revenue up 10% at Rs 1,945 cr

Revenue growth was primarily driven by good performance of its research services and biosimilars business segments

Sensex slips 336pts; Nifty Bank at new high; RIL falls 3%, TaMo DVR up 10%

Stock market LIVE: The broader markets also ended with notable losses as profit-taking continued for the third straight trading session, amid valuation and inflation concerns